Stock Comparison
ABBV vs JNJ: One Pharma Book, or Diversified Healthcare?
A head-to-head of AbbVie and Johnson & Johnson covering dividends, business mix, and payout record.
Data updated September 4, 2026
Best for
- ABBVInvestors who want higher current income (2.66% vs 1.90% for JNJ).
- JNJInvestors who want direct ownership of the underlying business, with no fund wrapper or management fee.
Visual comparison
Key metrics
Projected income on $10K
Projections assume the current yield and share price remain constant. Actual results will vary.
Total returns
ABBV has lagged JNJ over the trailing twelve months, posting a 24.81% total return against 58.12%. The picture flips over 10 years, though — ABBV has compounded at 19.61% a year, ahead of JNJ at 11.68%. JNJ has been the steadier holding, though — annualized volatility of 18.0% against 24.8% for ABBV. Figures are total returns: price change plus every distribution reinvested.
| Symbol | YTD | 1Y | 3Y | 5Y | 10Y | Since Dec 2012 | Volatility | Sharpe | Sortino | Max drawdown |
|---|---|---|---|---|---|---|---|---|---|---|
| ABBV | 14.48% | 24.81% | 24.89% | 22.51% | 19.61% | 20.27% | 24.8% | 0.72 | 0.99 | -20.7% |
| JNJ | 34.89% | 58.12% | 23.12% | 12.57% | 11.68% | 13.51% | 18.0% | 0.91 | 1.33 | -14.4% |
Total return with all distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date), split-adjusted, as of September 4, 2026. YTD and 1Y are cumulative; windows of one year or longer are annualized. “Since Dec 2012” measures every fund from December 10, 2012 — the youngest fund's first trading day — so all funds share one comparison window. Volatility is the annualized standard deviation of daily total returns over the trailing 3 years. Sharpe and Sortino divide the annualized return in excess of the risk-free rate by, respectively, that volatility and the downside deviation (both over the trailing 3 years) — higher is better. Max drawdown is the largest peak-to-trough total-return decline over the same window — shallower is better.
Side-by-side snapshot
| Metric |  ABBV |  JNJ |
|---|---|---|
| Full name | AbbVie Inc. | Johnson & Johnson |
| Issuer | — | — |
| Last Close | $256.46 as of September 4, 2026 | $275.23 as of September 4, 2026 |
| Distribution rate | 2.66% | 1.90% |
| Distribution Safety Score™ | 99 | 100 |
| Safety-Adjusted Yield | 2.63% | 1.90% |
| Expense ratio | — | — |
| AUM | — | — |
| Distribution frequency | Quarterly | Quarterly |
| Underlying index | — | — |
| Objective | Discovers, develops, manufactures, and sells pharmaceuticals in immunology, oncology, neuroscience, and eye care markets worldwide. | Researches, develops, manufactures, and sells healthcare products including pharmaceuticals, medical devices, and consumer health products worldwide. |
| Asset class | Equity | Equity |
| Inception date | N/A | N/A |
| Beta | 0.281 | 0.235 |
| Last dividend | $1.73 | $1.34 declared, pays 09/08/2026 |
| Ex-dividend date | 07/15/2026 | 08/25/2026 |
Bottom lineChoose ABBV if you want higher current income (2.66% vs 1.90% for JNJ). Choose JNJ if you want direct ownership of the underlying business, with no fund wrapper or management fee.
ABBV vs JNJ: pharma book or diversified healthcare?
AbbVie is concentrated in pharmaceuticals. Johnson & Johnson spreads across drugs, devices, and consumer. Mix is the decision.
| ABBV | JNJ | |
|---|---|---|
| Mix | Pharmaceuticals | Drugs, devices, and consumer |
| Payout | Quarterly dividend | Quarterly dividend |
| Distribution yield | 2.66% | 1.90% |
Income calculator
See how much monthly income a hypothetical investment would generate in each stock at current yields.
Want to go deeper?
Add these stocks to a sample portfolio and forecast your dividend income over 5+ years — free to start, no credit card.
Quick verdict
ABBV (AbbVie Inc.) and JNJ (Johnson & Johnson) are both quarterly-pay dividend-paying stocks, but they take different approaches.
ABBV offers the higher yield at 2.66% vs 1.90% for JNJ. A higher yield means more current income per dollar invested, though it may come with different risk characteristics.
Still deciding? Track ABBV & JNJ for free
Create a free Dividend Vision account to keep them on a watchlist, get notified when they declare dividends, and see how much income they would add to your portfolio.
Deep dive
Yield & income
On a $10,000 investment, ABBV would generate roughly $22.17/month, while JNJ would produce $15.83/month, at current distribution rates. Both pay quarterly distributions.
Strategy & risk
ABBV is a stock built around biopharmaceuticals exposure, while JNJ is a stock built around pharmaceuticals & medical devices exposure. Beta is 0.281 for ABBV and 0.235 for JNJ — effectively similar market sensitivity.
Security details
ABBV (AbbVie Inc.) is a stock. JNJ (Johnson & Johnson) is a stock.
Enjoyed this page?
Do us a favor — if you found this comparison useful, please share it with a friend researching dividend investments.
Frequently asked questions
What is the difference between ABBV and JNJ?
ABBV (AbbVie Inc.) is a large-cap pharmaceutical company. JNJ (Johnson & Johnson) mixes drugs, medical devices, and consumer health. Both pay quarterly. Distributions are 2.66% and 1.90% as of September 2026. Mix and concentration, not a small yield gap, are the decision.
What is the current distribution rate for ABBV and JNJ?
ABBV currently distributes 2.66% and JNJ 1.90%, based on fund data updated September 2026. Distribution rate moves with both the payout and the share price, so check the as-of date before relying on either figure.
Is ABBV or JNJ better for dividend income?
It depends on your goals. ABBV currently offers the higher distribution yield, which means more income per dollar invested. However, a lower-yield fund may offer better total return or lower volatility. Consider your time horizon and risk tolerance.
Can I hold both ABBV and JNJ?
Yes — nothing prevents holding both. Whether the combination actually diversifies depends on how much the underlying exposures overlap, which isn't fully measurable from the data on this page; review each security's holdings, sector, and strategy before treating them as complementary.
Is ABBV or JNJ safer?
By Dividend Vision's Distribution Safety Score — a rules-based 0–100 estimate of how resilient a distribution looks, where higher is safer — they are effectively tied: JNJ scores 100, ABBV scores 99. Neither has a clear safety edge on that measure. No score makes an investment risk-free — treat this as a screening signal, not a guarantee.
How much income does $10,000 in ABBV vs JNJ generate?
At current rates, $10,000 in ABBV would generate roughly $22.17 per month ($266.00 annually). The same in JNJ would produce about $15.83 per month ($190.00 annually).
Which has performed better historically, ABBV or JNJ?
ABBV has lagged JNJ over the trailing twelve months, posting a 24.81% total return against 58.12%. The picture flips over 10 years, though — ABBV has compounded at 19.61% a year, ahead of JNJ at 11.68%. JNJ has been the steadier holding, though — annualized volatility of 18.0% against 24.8% for ABBV. Figures are total returns: price change plus every distribution reinvested. Past performance does not guarantee future results.
More comparisons to explore
Popular comparisons
ABBV vs JNJ — at a glance
Generated September 5, 2026.
Overview
ABBV and JNJ are both large-cap healthcare stocks with diversified exposure to pharmaceuticals, but ABBV is a pure-play biopharmaceutical company focused on immunology, oncology, neuroscience, and eye care, while JNJ operates a broader healthcare conglomerate spanning pharmaceuticals, medical devices, and consumer health. The key distinction is ABBV's narrower, higher-risk focus versus JNJ's diversified revenue streams across three distinct business segments.
How they differ
ABBV offers a notably higher distribution rate at 2.66% versus JNJ's 1.90%, reflecting a more aggressive capital allocation strategy common in pure pharma plays. ABBV also shows higher systematic risk, with a beta of 0.281 compared to JNJ's 0.235, meaning ABBV historically amplifies broad market moves to a greater degree. Beyond yield and volatility, the structural difference is fundamental: ABBV derives all revenue from drug development and sales in specialized therapeutic areas, while JNJ buffers pharmaceutical fluctuations with medical device manufacturing and over-the-counter consumer brands—a significant portfolio-level hedge that ABBV lacks. ABBV was spun out from Abbott Laboratories in 12/10/2012, whereas JNJ traces back to 01/02/1962, lending JNJ a century-plus track record as a diversified incumbent.
Who each is best for
ABBV: Fits investors comfortable with single-industry concentration who prioritize current income and can tolerate above-market volatility in exchange for a higher yield and exposure to high-growth therapeutic categories like immunology and oncology.
JNJ: Designed for income-focused investors who value stability, diversification across business lines, and lower volatility, accepting a more modest distribution rate in exchange for the ballast of device and consumer segments and a long institutional history.
Key risks to know
- Concentration risk in ABBV. With all revenue tied to pharmaceutical development and regulatory approval, ABBV carries pipeline risk—a major clinical trial failure or loss of exclusivity on a key drug could significantly impair earnings. JNJ's device and consumer divisions provide earnings stability ABBV cannot match.
- Patent cliff exposure. Both face risk from drug patent expirations and generic competition, but ABBV's narrow therapeutic focus means a single loss of exclusivity has proportionally larger impact on consolidated results.
- Higher volatility in ABBV. The beta differential (0.281 vs. 0.235) reflects ABBV's greater sensitivity to biotech sentiment swings, sector rotation, and FDA news flow. Investors seeking predictable price action will find JNJ steadier.
- Medical device and litigations in JNJ. JNJ faces legacy litigation and regulatory scrutiny around its talc, opioid settlements, and device manufacturing practices, which could create unexpected legal or operational costs.
- Yield sustainability at ABBV. The higher 2.66% distribution rate requires consistent earnings growth and disciplined capital management to sustain without eroding shareholder value over time.
Bottom line
If you prioritize current income and can tolerate sector-specific risk and higher volatility, ABBV's 2.66% yield and pure-play pharma exposure stand out. If you want a lower-volatility, diversified healthcare company with a more modest but arguably more durable dividend, JNJ's stability across three business segments fits that profile better. Past performance does not guarantee future results.
AI-generated analysis for educational purposes only. Verify important details independently; past performance does not guarantee future results.
Learn the method
The metrics behind this comparison, explained in the Academy.
Still deciding? Compare them against your own portfolio
See how each stock fits alongside your real holdings — forecast future income, analyze overlap, and gauge risk. Start a free 7-day Dividend Vision trial and make the call with your full portfolio in view.